About 73 employees are affected, according to Lyell Immunopharma, Inc.'s latest layoff filing, on April 1, 2025. As of November 15, 2026, Lyell Immunopharma, Inc. has reported this one exit or restructuring plan to the SEC on Form 8-K under Item 2.05. No WARN notice under its name is on file in the states covered here (Form 8-K, April 1, 2025).
10 companies announced layoffs this week, 1 had other signals.
Companies cutting jobs this week. Before you unlock: the company, the number of employees and what is inside. After: every way we found to reach the company. No individual is named in a layoff.
| UPWORK, INC | announced layoffs | |
| PVH CORP. /DE/ | announced layoffs | |
| Battelle | filed a layoff notice for 15 employees | |
| TidalHealth Primary Care | filed a layoff notice for 5 employees | |
| Phunware, Inc. | announced layoffs |
Is this your company?
Owed money by them or selling to them? See the free Snapshot of Lyell Immunopharma, Inc.
Free to see. No signup.
People from Lyell Immunopharma, Inc. who say they are open to work
Only people who added themselves are listed here. Nobody is named because of a company announcement or a news story, and we have not checked what anyone says about themselves.
Loading the list…
Affected by the Lyell Immunopharma, Inc. layoff? Add yourself to the open-to-work list, free
Your entry
Lyell Immunopharma, Inc. reported 1 exit or restructuring plan on Form 8-K under Item 2.05, 1 of 1 stating how many employees or positions are affected. Each fact below is the filing's own sentence, quoted and linked. No WARN notice under this company's name is on file in the states covered here.
Did Lyell Immunopharma have layoffs in 2025? What its filings say
Lyell Immunopharma, Inc. (CIK 1806952) reported 1 exit or restructuring plan to the SEC on Form 8-K under Item 2.05. The sentences below are quoted from the filings as written.
Form 8-K filed 2025-04-01
Employees affected
The Board also approved the reduction of the Company's workforce in West Hills by approximately 73 employees related to such closure.
Locations
As a result, on March 31, 2025, Lyell's Board of Directors (the "Board") approved the closure of the West Hills manufacturing facility acquired as part of Lyell's acquisition of ImmPACT Bio in 2024.
Expected charges
In connection with these actions, the Company expects to incur aggregate expenses of between $3.0 million to $4.0 million, related to severance, benefits, payroll taxes, and other workforce reduction costs, which are expected to be recognized primarily in the second and third quarters of 2025.
Also on the record for Lyell Immunopharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2026 | Stake report, Schedule 13G/A, by ARCH Venture Fund IX, L.P. | 17.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by James B. Tananbaum | 2.7% of the class | 5%+ stakes | Source |
| June 18, 2026 | Stake report, Schedule 13G/A, by Innovative Cellular Therapeutics Holdings Limited | 12.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by ARCH Venture Fund IX, L.P. | 13.9% of the class | 5%+ stakes | Source |
| May 11, 2026 | Stake report, Schedule 13G/A, by MWG Caph Ltd | 4.3% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G/A, by Explore Investments LLC | 6.6% of the class | 5%+ stakes | Source |
| April 21, 2026 | Stake report, Schedule 13G, by EULER FUND, L.P. | 6.71% of the class | 5%+ stakes | Source |
| March 9, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by ARCH Venture Fund IX, L.P. | 13% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by James B. Tananbaum | 7.6% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G, by Innovative Cellular Therapeutics Holdings Ltd | 9.8% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by Newton (PTC) Limited | 3.93% of the class | 5%+ stakes | Source |
Keep reading
More on Lyell Immunopharma, Inc. and the records around it.
Lyell Immunopharma, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Gates Frontier, LLC also filed stake reports on 1 other company: Evolv Technologies Holdings, Inc. (Sep 2025)
- Newton (PTC) Limited also filed stake reports on 1 other company: Figure Technology Solutions, Inc. (Nov 2025)
- ARCH Venture Fund IX, L.P. also filed stake reports on 2 other companies: Vir Biotechnology, Inc. (Nov 2026), Sana Biotechnology, Inc. (Aug 2026)
Watch Lyell Immunopharma, Inc.
Get an email when Lyell Immunopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Lyell Immunopharma, Inc.?
Want the whole picture on Lyell Immunopharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Lyell Immunopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lyell Immunopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Tools for this story
Each opens in a new tab, filled in for Lyell Immunopharma, Inc.. With no account yet, you sign up free and land on the result.
Public companies must also report to the SEC, on Form 8-K under Item 2.05, when they commit to an exit or restructuring plan that will cost them material charges, which is how most large layoffs and closures by listed companies are disclosed. Those filings are national, so they cover companies in every state. Each sentence shown from one is quoted exactly and linked to the filing; where a filing does not state a figure, none is shown.
Where this comes from
Employers covered by the federal WARN Act, and by the stricter laws some states add, must give written notice before a mass layoff or a site closure. The state labor department publishes those notices. Every row here is one of them, taken from that state's own published file and linked to it, so each figure can be checked at the source.
A notice states the employer, the location, the number of employees affected, and when the layoff or closure takes effect. It does not state a reason, and neither does this page. Where a company also appears in SEC filings under the same name and in the same state, its recorded fundraising is shown alongside, as a matter of record rather than as an explanation. New Jersey and Pennsylvania list a notice under the month it was posted or received, not the day, so their notices show a month. Tennessee gives the county rather than the city.
Who owns Lyell Immunopharma, Inc.? Owners, funding and legal record
Cite this page
https://mentionfox.com/layoffs/lyell-immunopharma